Search

Displaying results 2331 - 2340 of 10000 in total
  1. Target

    Actin-related protein 2/3 complex subunit 4

    go.drugbank.com/bio_entities/BE0004254
    TargetHumans

    Actin-binding component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 4Synonyms: Arp2/3 complex 20 kDa subunit
  2. Target

    Actin-related protein 2/3 complex subunit 5

    go.drugbank.com/bio_entities/BE0004255
    TargetHumans

    Component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 5Synonyms: Arp2/3 complex 16 kDa subunit
  3. Drug

    Resorcinol

    go.drugbank.com/drugs/DB11085
    ApprovedInvestigational

    Resorcinol is a 1,3-isomer (or meta-isomer) of benzenediol with the formula C6H4(OH)2. It is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborr...

    Synonyms: m-Hydroquinone, m-hydroxyphenolMixtures: FUCSINA FENICA MARCO VITI, BUCO-BLEU KOLLUTUVAR, 15 ML
  4. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

  5. Drug

    Ziconotide

    go.drugbank.com/drugs/DB06283
    ApprovedInvestigational

    [A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.

    Categories: Complex Mixtures
  6. Drug

    Florfenicol

    go.drugbank.com/drugs/DB11413
    ExperimentalVet approved

    Florfenicol is a fluorinated synthetic analog of thiamphenicol.

    Products: Florcol Oral Solution 250mg/ml
  7. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20

  8. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disea...

    Mixtures: Produodopa 240 mg/ml + 12 mg/ml Infusionslösung
  9. Drug

    Dipotassium phosphate

    go.drugbank.com/drugs/DB09414
    ApprovedInvestigational

    Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.

    Mixtures: ENJEKSIYONLUK POTASYUM FOSFAT 20 ML, 20 AMPUL, 5% Travasol Amino Acid Injection With Electrolytes In 20% Dextrose
  10. Drug

    Elasomeran

    go.drugbank.com/drugs/DB15654
    ApprovedInvestigational

    [L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). … [L28026] On December 23, 2020, Health Canada issued an expedited authorization for the Moderna COVID-19 Vaccine.